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USA (APC: −2.9 %; 2004–2010), Canada (APC: −2.9 %; 
2006–2011) and England (APC: −2.6 %; 2003–2008) 
decreased at a faster rate compared with Australia (APC: 
−1.7 %; 1997–2011). In 2010, mortality rates were highest 
in England and Australia (23.8/100,000 in both countries). 
The mortality gap between Australia and USA grew from 
1994 to 2010, with a total of 10,895 excess prostate cancer 
deaths in Australia compared with US rates over 17 preced-
ing years.
Conclusions Prostate cancer incidence rates are likely 
heavily influenced by prostate-specific antigen testing, but 
the fall in mortality occurred too soon to be solely a result 
of testing. Greater emphasis should be placed on address-
ing system-wide differences in the management of pros-
tate cancer to reduce the number of men dying from this 
disease.
Abstract 
Purpose To compare prostate cancer incidence and mor-
tality rates in Australia, USA, Canada and England and 
quantify the gap between observed prostate cancer deaths 
in Australia and expected deaths, using US mortality rates.
Methods Analysis of age-standardised prostate cancer 
incidence and mortality rates, using routinely available 
data, in four similarly developed countries and joinpoint 
regression to quantify the changing rates (annual percent-
age change: APC) and test statistical significance. Expected 
prostate cancer deaths, using US mortality rates, were cal-
culated and compared with observed deaths in Australia 
(1994–2010).
Results In all four countries, incidence rates initially 
peaked between 1992 and 1994, but a second, higher 
peak occurred in Australia in 2009 (188.9/100,000), ris-
ing at a rate of 5.8 % (1998–2008). Mortality rates in the 
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Purpose
Over the past two decades, prostate cancer incidence rates 
have risen substantially in many developed countries. How-
ever, trends in mortality have been less dramatic and show 
considerable variation, especially between developed coun-
tries [1]. In Australia, prostate cancer incidence rose 144 % 
from 1982 to 2009, while mortality decreased 30 % from 
1993 to 2010 [2]. Australian prostate cancer incidence rates 
are among the highest internationally, yet the reduction in 
mortality appears somewhat modest compared with other 
developed countries. Differences in prostate-specific anti-
gen (PSA) testing practices appear to account for variations 
in incidence, whereas differences in mortality are not so 
clearly explained [3]. It has been proposed that differential 
mortality could be partially attributed to earlier detection 
and improvements in surgical and radiotherapy methods 
used for localised prostate cancer and increased the use of 
androgen deprivation therapy (ADT) and chemotherapy for 
men with later stage disease [4–6].
To quantify the apparent disparity between Australia 
and other developed countries in prostate cancer mortality, 
we analysed and compared incidence and mortality data in 
four countries. All four countries were recently classified 
as experiencing “earlier mortality decline” [1] for prostate 
cancer. Our aims were to:
1. Describe the trends in incidence and mortality rates 
from prostate cancer in four developed countries—
Australia, England, USA and Canada—to better under-
stand the differences in mortality between Australia 
and these countries;
2. Quantify the gap between observed prostate cancer 
deaths in Australia and expected deaths, using the 
country with the largest fall in mortality rates (USA) as 
a benchmark.
Methods
In addition to Australia, the three nations were selected 
from the larger group 15 countries with “earlier mortality 
decline” as they have similar demographic compositions 
but had differing approaches to PSA testing from the 1990s 
compared to Australia: USA had high screening rates asso-
ciated with higher awareness and media attention given to 
PSA testing, Canada also had high screening rates but with 
regional variation [7], and England had notably lower rates 
of PSA testing [8, 9]. Data on the number of prostate cancer 
deaths and newly diagnosed cases by 5-year age group and 
year were obtained for all four countries from publically 
available sources (Table 1). The age-standardised rates for 
each country were calculated using the European popula-
tion as the reference population [10]. We also subdivided 
the data into two age groups for more detailed analysis—
under 65 and over 65 years for incidence and under 75 and 
over 75 years for mortality. Subgroupings were based on 
the median ages of diagnosis and death for Australian men.
Joinpoint regression was used to quantify the gradient 
of change in incidence and mortality rates over time and 
test their statistical significance. Joinpoint regression sum-
marised trends over successive segments of time, and the 
annual percentage change (APC) was calculated for each 
time segment. The joinpoint regression was not restricted 
and allowed for the best fit, that is, where the APC was sig-
nificantly different from 0 at α = 0.05 [11].
In addition, the number of observed prostate cancer 
deaths in Australia from 1994 to 2010 was compared with 
the number of expected deaths, using age-specific mortality 
rates from the USA and the Australian population by year. 
A similar method has previously been used by Sitas et al. 
[12] to quantify the change in Australian cancer incidence 
and mortality over 20 years. The year 1994 was chosen as 
it marked the first year of decline after the peak of prostate 
cancer mortality in Australia. The USA was selected as the 
benchmark as their mortality rates were the lowest of the 
four countries used in this study. This allowed us to quan-
tify the gap between observed deaths in Australia and the 
number of deaths expected if Australia had experienced the 
same age-specific rates by year as in the USA. The stand-
ardised mortality ratio was calculated to test for statistical 
significance, with 95 % confidence intervals. No ethical 
approval was required for this study.
Results
The age-standardised incidence rates and joinpoint regres-
sion for incidence in all four countries using all avail-
able data are shown in Fig. 1 and Table 2, respectively. 
Incidence in the USA initially peaked earlier (1992: 
216.2/100,000) than Australia (1994: 164.9/100,000) and 
Canada (1993: 146.7/100,000), whereas England had a 
steady incline from 1987 onwards. From 1990–1994 to 
1994–1998, the gradient of change in Australian incidence 
rate in men of all ages dropped from 20.1 %, largely attrib-
uted to a sharp rise in men under 65 years of age (APC: 
41.9 %), to a more modest decline in men of all ages (APC: 
−10.1 %). However, the incidence did not return to the lev-
els reported prior to the 1994 peak. Both Canada and the 
USA had periods of falling incidence in the early 1990s 
and again in the 2000s. Only the USA has had a continuing 
1679World J Urol (2015) 33:1677–1687 
1 3
reduction in incidence in the most recent period (APC: 
−1.6 %; 2000–2010). Canadian rates were decreasing, and 
recent figures showed increasing incidence in men under 
65 (APC: 2.0 %; 2001–2007). In contrast to the sharp peak 
seen in the other three countries, the incidence rate in Eng-
land had a steadier incline and continued to rise, albeit 
at a lower rate of change (APC: 1.1 %; 2001–2011). The 
most recent available incidence data showed that the age-
standardised rates were highest in Australia at 167/100,000 
(2010), followed by USA at 147.2/100,000 (2010) then 
Canada at 133/100,000 (2007) and lowest in England at 
107.4/100,000 (2011).
The standardised mortality rates and joinpoint regression 
for mortality in all four countries using all available data are 
shown in Fig. 2 and Table 3, respectively. Mortality peaked 
in the early 1990s for all four countries, firstly in the USA 
(1991: 30/100,000), then England (1992: 30.7/100,000) 
with Australia (34.3/100,000) and Canada (32.6/100,000) 
both reaching the highest mortality rate in 1993. The most 
recent available data showed that the age-standardised mor-
tality rates were highest in England at 23.8/100,000 (2010), 
with Australia following closely behind at 23.4/100,000 
(2011) and lowest in the USA at 16.5/100,000 (2010), with 
a similar low rate in Canada at 16.7/100,000 (2011).
In the most recent time period, the rate of change in Aus-
tralian mortality slowed (APC: −1.7 %; 1997–2011), as did 
American mortality which dropped from −4.0 % in 1994–
2004 to −2.9 % in 2004–2010. In Canada there tended to 
be a slight increase on a similar trajectory compared to that 
seen prior to the highest mortality rate reported in 1993, 
whereas the consistent mortality reduction in England was 
interrupted by a period of increase from 2000 to 2003 (not 
statistically significant).
To quantify the absolute difference in the number of 
deaths between the USA and Australia, we obtained the 
number of observed deaths from prostate cancer in Aus-
tralia from 1994 to 2010 and the number of expected 
deaths, after applying the annual US age-specific mortality 
rates. There were an additional 10,895 deaths in Australian 
men than would have been expected during the 17 years of 
this study. The difference in number of deaths rose from 
393 deaths (17.7 %) in 1994 to 1,042 deaths (47.8 %) in 
2010.
Discussion
Our analysis showed that while mortality rates in Australia 
have decreased from 1994 onwards, they have done so at 
a different trajectory to rates in the USA, Canada or Eng-
land. The US mortality rate (per 100,000) dropped from 
30.0 (1992) to 16.5 (2010) and Australia dropped from 
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reduction in the USA compared with only 25 % in Aus-
tralia. Mortality rates in the USA and Canada have shown 
a greater decline since the mid-1990s than Australia, 
whereas England reached a similar rate to Australia in the 
early 2000s and has stabilised at a slower and less consist-
ent rate.
Importantly, these results show that, had Australia 
experienced mortality rates similar to those of the USA, 
almost 11,000 deaths from prostate cancer might have been 
averted (1994–2010). Australian cancer patients have the 
highest estimated survival in the world (30 deaths for every 
100 new cases for all cancers [13]. However, for prostate 
cancer, there are 14 deaths for every 100 new cases in 
Australian men, whereas in the USA, there are 11 deaths 
for every 100 new cases [13]. When compared to other 
common cancers, we can see that there are fewer deaths 
in Australians with lung and colorectal cancer (69/100 
and 24/100, respectively) than in Americans (74/100 and 
37/100, respectively). However, for breast cancer (female 
only), there is no difference between the two countries with 
16 deaths per 100) [13]. This suggests that cancer control 
measures in Australia generally result in better outcomes 
than in the USA, with the exception of prostate cancer, 
increasing the imperative to better understand prostate can-
cer trends. The disparities between these countries are not 
well understood, and our analysis highlighted time periods 
when mortality changed significantly.
PSA testing and prostate cancer incidence
Prostate cancer incidence rates are largely influenced by 
PSA testing. Key randomised controlled trials identified 
small mortality benefits associated directly with PSA test-
ing, but this has not resulted in global population-wide 
screening recommendations to date as the evidence is 
inconsistent [3, 14–17]. Generally, men over 50, or over 40 
with a family history of prostate cancer, are encouraged to 
discuss the possibility of PSA testing with their doctor, but 
updated US guidelines now recommend against PSA test-
ing [18].
Differences in the uptake and use of PSA testing in 
each of the countries in this study are likely to account 
for a major proportion of incidence rate differences [12]. 
Over the time period analysed, PSA testing recommenda-
tions from peak bodies in each country varied. While no 
formal screening programs existed, PSA testing was gen-
erally widespread in certain areas with men encouraged 
to make informed decisions [19]. The current guidelines 
in the USA, UK and Canada do not recommend PSA test-
ing for healthy, or asymptomatic, men [18, 20–22]. Aus-
tralia’s recently released updated draft guidelines support 
testing every 2 years for healthy men between 50 and 69 
if requested, and after sufficient information is provided on 
the benefits and harms, but PSA testing is not supported in 
individuals with <7 years’ life expectancy [23]. Variations 
Fig. 1  Age-standardised prostate cancer incidence rates
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to national recommendations similar to the Australian 
approach are also seen in some regions of Canada [24].
However, a direct comparison of testing rates in each 
country is difficult due to the lack of centrally held relevant 
data. Since the introduction of PSA testing in 1988, Aus-
tralia has demonstrated higher rates of negative transrectal 
ultrasound-guided systemic biopsies and a higher incidence 
of low/intermediate grade prostate cancer in males younger 
than 55 in which cases would have gone previously unde-
tected [25]. This may have contributed to the rise in inci-
dence of Australian men under 65 from 1999 to 2008 
(APC: 10.3 %).
Incidence rates in the USA and Australia decreased in 
the most recent period, despite the high rates of PSA testing 
reported with 75 % of men over 50 tested in the USA [26] 
and 64 % of men between 40 and 74 having been tested 
at least once in Australia [27]. The emerging evidence of 
a reduction in incidence in the USA and Australia is not 
immediately explicable, perhaps due to the more conserva-
tive use of PSA testing. Data from the USA support this 
possibility showing that PSA testing dropped after the 
updated guidelines [28, 29]. However, these studies also 
incorporate data predating this recommendation so future 
rates may decline further.
Conversely, the incidence of prostate cancer in Eng-
land and Canada continued to increase during the most 
recent period of analysis. The lower UK incidence rates 
in comparison with the other countries are considered to 
be due to consistently low PSA testing rates. In 2007, the 
screening rate of asymptomatic men from 45 to 89 in the 
UK was 6.2 %, and prior to this, PSA testing was discour-
aged [8, 30]. In Canada, 53.8 % of males over 35 years of 
age had a PSA test in 2008 [31], with standard practice 
incorporating annual PSA testing [22].
Prostate cancer treatment and mortality
While the changes in incidence are likely due to changes 
in testing behaviours identifying the causes for changes in 
prostate cancer mortality trends is more challenging. Early 
reports investigated the impact of PSA testing on prostate 
cancer mortality, and estimates suggest that the potential 
survival benefits take over 10 years to accrue [3, 32]. As a 
consequence, the drop in mortality, first apparent in Aus-
tralia just 6 years after the introduction of PSA testing, was 
too soon to be a result of screening. If PSA testing were to 
have made a high impact on mortality, an accelerated rate 
of decreasing mortality would have been evident earlier. A 
similar conclusion was drawn from a Scottish study where 
increased detection did not clearly drive decreasing pros-
tate cancer mortality [33].
The recording and coding of cause of death have been 
excluded as a driver of prostate cancer mortality changes 
with good agreement found between cause of death 
Fig. 2  Age-standardised prostate cancer mortality rates
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reported on death certificates and medical records in pros-
tate cancer patients in the USA [34, 35]. However, a UK 
study suggested that changes to national coding practices 
resulted in an artificial increase in prostate cancer mortality 
from 1984 to 1992 and a decline after 1993 [36]. However, 
our joinpoint analysis for Australia, England and Canada 
showed little evidence of any increase in mortality during 
the first years of PSA testing, meaning misattribution was 
unlikely to be a major cause of any rise prior to the sus-
tained fall observed.
The reduction in mortality in all four countries is likely 
due in part to improvements in treatment which is associ-
ated with improved survival [35, 37], especially of men 
with localised disease. Much of the prostate cancer treat-
ment innovation has historically been initiated in the USA 
[38]. For example, radical prostatectomy (RP), for the 
treatment of localised prostate cancer, has higher reported 
usage in the USA. Its effectiveness in reducing prostate 
cancer mortality and the risk of disease progression was 
shown in men under 65 with 23 years follow-up [39], but 
in men under 75 years of age, the reduction in mortality 
was not statistically significant when compared to watchful 
waiting over a 10-year period [40]. The theory that diverse 
treatment methods are a major driver of disparities in mor-
tality has not been conclusively proven and requires further 
investigation [38, 41]. RP treatments are now the most fre-
quent treatment method used among men with clinically 
localised prostate cancer in Australia with decreasing use 
of hormonal therapy as a primary treatment [42]. From 
2000 to 2006, there was a 53 % increase in RPs in England 
resulting from an increasing number of surgeons with the 
ability and willingness to perform the procedure [43]. How-
ever, a comparison of prostate cancer mortality in the USA 
and England showed significantly lower mortality rates in 
the USA, possibly explained by the lower prevalence of 
radical therapy in England [44]. While direct comparisons 
are not simple, evidence of differences in international vari-
ations in the use of active surveillance, local treatment and 
systemic therapy has been documented during the period of 
study [45].
Once clinical innovations are demonstrated, there is 
often a delay in their integration into routine practice. For 
prostate cancer treatment, the diffusion of robotic RPs was 
greater in the USA. By the mid-2000s, over 5,000 robotic 
RPs were performed worldwide of which approximately 
4,800 were in the USA [46]. On the other hand, in Aus-
tralia, robotic surgeries increased from 3 in 2003 to 2,775 
in 2011, with robotic RP being the most common [47]. The 
impact of robotic RP on mortality is still being investigated 
as their effectiveness has been largely identified in the 
improvement in functional, patient-related outcomes rather 
than survival outcomes but this requires further investiga-
tion [48, 49]. However, these findings illustrate the higher 
and more immediate use of innovative techniques in the 
USA compared with other countries. Future innovations, 
such as the use of multi-parametric magnetic resonance 
imaging in the diagnosis of prostate cancer, to confirm 
staging and grading as well as planning for treatment, may 
further improve outcomes [50].
Much of the current debate in the medical, public health 
and broader communities is the high diagnosis rate and 
overtreatment of prostate cancer, especially low-risk cases 
[3–5, 14, 15, 32, 39–43, 51]. It is possible that higher 
screening prevalence in the USA, which occurred earlier 
than in other countries, may have detected more later stage 
prostate cancer cases and could have led to subsequent 
curative treatment or prolonging life sufficiently that the 
cause of death was not attributed to prostate cancer. Again, 
the comparison of national data collections on disease stage 
is hampered by the lack of internationally comparable data. 
The limited information available on prostate cancer treat-
ments in Australia has been recognised, and, as a result, ini-
tiatives are also underway to compile a National Prostate 
Cancer Registry, based on the successful Victorian model 
[52]. However, a Swedish study suggests that the intensity 
of opportunistic screening has a greater effect on reducing 
prostate cancer mortality [53]. This may have contributed 
to the lower mortality in the USA, but the high levels of 
opportunistic screening in Australia should have results in 
similar mortality reductions, which are not evident in the 
available data.
A lack of systematic follow-up and treatment for men 
with high-risk disease after initial treatment may also be a 
potential area for improvement. Data from the USA suggest 
a more aggressive approach in these patients with high-risk 
features may be associated with differences in death rates. 
The use of ADT alone has been shown to reduce death from 
prostate cancer but may increase the risk of death from 
competing causes [5]. Recent evidence from randomised 
controlled trials has shown that overall survival of patients 
with locally advanced prostate cancer increases if they are 
given radiotherapy in addition to ADT, rather than the tra-
ditional treatment of ADT alone [54, 55]. Chemotherapy 
is considered an effective treatment for later stage prostate 
cancer, but it has lower uptake in older men, requires fur-
ther lines of treatment to reduce the risk of death [6, 56] 
and likely only contributes a very small proportion of years 
of life gained in men treated.
The differences in healthcare systems in all four coun-
tries are likely to be partially responsible for differences 
in mortality trends [57] However, a previous study com-
pared the divergence between USA and UK prostate can-
cer mortality trends with all-cancer mortality, finding little 
difference between the two [38] The study suggested that 
the detection or treatment differences for prostate can-
cer were likely the cause of differences between the two 
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countries rather than any difference in systemic healthcare 
approaches [38].
Limitations
The main limitation of our study is the ecological approach 
taken. This is an observational study using routinely avail-
able population-wide statistics. While it allows us to 
quantify the difference between Australia and other simi-
lar developed countries, it restricts the detailed interpreta-
tion of results and our ability to identify the reasons for 
the observed differences, and thus, it has reduced clinical 
relevance. An understanding of broad population-wide 
approaches to prostate cancer suggests that diagnosis and 
treatment patterns contribute to the differences. The possi-
ble effect of genetic or lifestyle factors on incidence and 
mortality has not been considered and is a limitation of this 
study. Existing publicly available data sources are not cur-
rently sufficient to explore the possible relationships on a 
population-wide level that have been suggested in previous 
work [58].
Conclusions
In Australia, it is projected that there will be 25,000 new 
cases of prostate cancer by 2020 [59], contributing an 
estimated large component of healthcare expenditure 
relating to male cancers. While the declining mortality 
is clearly evidence of progress being made in controlling 
prostate cancer, our understanding of the reasons for this 
improvement is limited. Overall, the change in mortality 
appeared too early to be solely attributed to PSA testing, 
it is more likely the results of advancement in treatment, 
both for men with localised disease but also and perhaps 
more importantly men with high-risk disease [30]. We have 
confirmed that Australian prostate cancer mortality is not 
declining at rates comparable with other developed coun-
tries. Almost 11,000 deaths from prostate cancer may have 
been averted between 1994 and 2010 if Australia’s prostate 
cancer mortality rate had been equal to that of the USA. 
Further emphasis should be placed on confirming why this 
inequality in outcomes existed with more detailed informa-
tion such as stage at diagnosis, treatment methods, screen-
ing techniques and diagnostic methods that may have 
influenced mortality trends. Continued effort and empha-
sis should be placed on monitoring patterns of care and 
outcomes of prostate cancer patients, and, as appropriate, 
system-wide differences should be addressed to reduce the 
number of men dying from this disease.
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